Study Country Study design N° COC Duration PCOS patients type and dose months diagnostic criteria Morin-Papunen et al, 2003 Finland Randomized open trial 10 EE 35 μ g/ CPA 2 mg 06 NIH Ibanez and de Zegher, 2004 Belgium/ Spain Randomized open trial 16 EE 30 μ g/ DRSP 3 mg 09 Rotterdam Ibanez et al, 2005 Spain/ Belgium Randomized open trial 21 EE 30 μ g/ DRSP 3 mg 03 Rotterdam Cagnacci et al, 2006 Italy Randomized open trial 10 EE 35 μ g/ CPA 2 mg 06 NIH Cagnacci et al, 2006 Italy Randomized open trial 10 EE 30 μ g/ DSG 0.15 mg 06 NIH Banaszewska et al, 2007 USA Crossover open trial 24 EE 20 μ g/ DSG 0.15 mg 03 Rotterdam Gul et al, 2008 Turkey Non-randomized open trial 30 EE 35 μ g/ CPA 2 mg 03 Rotterdam Hoeger et al, 2008 USA Randomized open trial 11 EE 30 μ g/ DSG 0.15 mg 06 NIH Bilgir et al, 2009 Turkey Randomized open trial 20 EE 35 μ g/ CPA 2 mg 03 Rotterdam Kebapcilar et al, 2010 Turkey Randomized open trial 28 EE 35 μ g/ CPA 2 mg 03 Rotterdam Chen et al, 2010 Taiwan Non-randomized open trial 56 EE 35 μ g/ CPA 2 mg 03 Rotterdam Mancini et al, 2010 Italy Non-randomized open trial 28 EE 30μ g/ DRSP 3 mg 06 Rotterdam Teede et al, 2010 Australia Randomized open trial 26 EE 35 μ g/ CPA 2 mg 06 NIH Tfayli et al, 2011 USA Non-randomized open trial 20 EE 30 μ g/ DRSP 3 mg 06 NIH Essah et al, 2011 USA Randomized open trial 10 EE 35 μ g/ NGM 0.18-0.25 mg 03 Rotterdam Kilic et al, 2011 Turkey Randomized open trial 49 EE 30 μ g/ DSG 0.15 mg 06 Rotterdam Ibanez et al, 2011 Belgium/ Spain Randomized open trial 17 EE 35 μ g/ CPA 2 mg 06 NIH Gode et al, 2011 Turkey Non-randomized open trial 40 EE 35 μ g/ CPA 2 mg 06 Rotterdam Vieira et al, 2012 Brazil Randomized open trial 21 EE 30 μ g/ CMA 2 mg 12 Rotterdam Diaz et al, 2012 Spain/ Belgium Randomized open trial 14 EE 35 μ g/ CPA 2 mg 12 NIH Harmanci et al, 2013 Turkey Non-randomized open trial 23 EE 30 μ g/ DRSP 3 mg 06 Rotterdam Ibanez et al, 2013 Spain/ Belgium Randomized open trial 17 EE 35 μ g/ CPA 2 mg 18 NIH Christakou et al, 2014 Greece Non-randomized open trial 40 EE 35 μ g/ CPA 2 mg 06 NIH Christakou et al, 2014 Greece Non-randomized open trial 40 EE 30 μ g/ DRSP 3 mg 06 NIH Glintborg et al, 2014 Denmark Randomized open trial 23 EE 30 μ g/ DSG 0.15 mg 12 Rotterdam Kahraman et al, 2014 Turkey Randomized open trial 19 EE 35 μ g/ CPA 2 mg 12 AES Kahraman et al, 2014 Turkey Randomized open trial 20 EE 30 μ g/ DRSP 3 mg 12 Rotterdam Dardzinska et al, 2014 Finland Crossover open trial 42 EE 35 μ g/ CPA 2 mg 04 Rotterdam Yildzhan et al, 2015 Turkey Randomized open trial 56 EE 30 μ g/ DRSP 3 mg 06 Rotterdam Yildzhan et al, 2015 Turkey Randomized open trial 50 EE 30 μ g/ CMA 2 mg 06 Rotterdam Orio et al, 2016 Italy Randomized double-blind trial 47 EE 35 μ g/ CPA 2 mg 06 Rotterdam